Supplemental Table 1. Treatment considerations at time of starting antiretroviral therapy (ART) and at time of survey

among those diagnosed at least one year ago, stratified by region and gender/sexual orientation


aniong those diagnosed at least one year ago, strain	HIGH INCOME COUNTRIES (HICs)			MIDDLE INCOME COUNTRIES (MICs)	
		% who		% who	
		perceived		perceived	
	% who perceived	issue as	% who perceived	issue as	
	issue as important	important	issue as important	important at	
	at time of starting	at time of	at time of starting	time of survey	
	treatment a	survey b	treatment ^a	b	
MEN WHO HAVE SEX WITH MEN (MSM)	MSM IN HICs (N		MSM IN MICs ((N = 137)	
To ensure side effects would be minimal	59.8	73.1	64.2	75.9	
To ensure that the virus was suppressed enough so that I			-		
could not pass it on to a partner	52.4	67.5	63.5	62.0	
To minimize the long-term impact of HIV treatment	47.9	66.1	36.5	61.3	
To manage symptoms or illnesses caused by HIV	53.9	58.2	53.3	51.1	
To keep the number of HIV medicines in my treatment to a	33.3	55.2	30.0	01.1	
minimum	34.5	53.8	35.0	55.5	
To allow flexibility as to when I have to take the HIV	5 1.6	55.5	33.0	00.0	
medication (time of day, with or without food, etc.)	37.5	49.7	43.8	54.0	
To ensure it was compatible with other	37.3	17.7	13.0	31.0	
medications/drugs/pills I was taking	29.8	43.4	24.8	35.0	
That the treatment is available in my public health facility	25.3	32.1	62.8	61.3	
The cost of the medication	22.8	27.9	15.3	24.1	
To have the best option to allow me to have children	4.5	10.1	6.6	13.9	
MEN WHO HAVE SEX WITH WOMEN (MSW)	MSW IN HICs (N		MSW IN MICs		
To ensure side effects would be minimal	42.7	45.5	47.0	69.2	
To ensure that the virus was suppressed enough so that I	42.7	43.3	47.0	09.2	
could not pass it on to a partner	41.2	37.3	43.6	70.9	
To minimize the long-term impact of HIV treatment	37.9	46.1	45.3	62.4	
To manage symptoms or illnesses caused by HIV	42.1	41.8	59.8	54.7	
	42.1	41.0	39.0	54.7	
To keep the number of HIV medicines in my treatment to a minimum	32.7	35.8	41.9	56.4	
	32.7	33.0	41.9	50.4	
To allow flexibility as to when I have to take the HIV	22.1	22.1	24.2	5 2.0	
medication (time of day, with or without food, etc.)	32.1	32.1	34.2	53.8	
To ensure it was compatible with other	24.2	25.0	20.2	40.7	
medications/drugs/pills I was taking	34.2	35.8	28.2	48.7	
That the treatment is available in my public health facility	30.6	31.2	33.3	52.1	
The cost of the medication	30.3	30.6	23.9	31.6	
To have the best option to allow me to have children	27.9	27.3	37.6	49.6	
WOMEN	WOMEN IN HICs (N =		WOMEN IN MICs (N =	•	
To ensure side effects would be minimal	46.4	57.3	50.0	64.3	
To ensure that the virus was suppressed enough so that I	27.5	500	F. 7.	(2.2	
could not pass it on to a partner	37.5	50.8	57.1	63.2	
To minimize the long-term impact of HIV treatment	38.4	54.4	40.7	55.5	
To manage symptoms or illnesses caused by HIV	48.2	48.2	56.6	51.1	
To keep the number of HIV medicines in my treatment to a					
minimum	33.8	45.3	29.7	48.4	
To allow flexibility as to when I have to take the HIV	_		_		
medication (time of day, with or without food, etc.)	29.3	36.9	39.6	50.0	
To ensure it was compatible with other	_		_		
medications/drugs/pills I was taking	32.3	37.7	29.1	47.3	
That the treatment is available in my public health facility	22.1	29.3	48.4	53.3	
The cost of the medication	23.4	26.9	17.6	24.2	
To have the best option to allow me to have children	20.0	19.5	30.8	35.2	

Note: MSM = men who have sex with men; MSW = men who have sex with women; MICs = Middle-income countries; HIC = High-income countries.

a Assessed with the question: "When you first started HIV treatment, other than ensuring that it was effective, what were your most important considerations?" Multiple response options could be

b Assessed with the question: "And imagine that you were starting HIV treatment today. Other than ensuring that it is effective, what would be your most important considerations?"

Supplemental Figure 1. Prevalence estimates among men who have sex with men (MSM), men who have sex with women (MSW), and women for selected negative health outcomes



Supplemental Figure 2. Treatment considerations at time of starting ART and at time of survey among those diagnosed at least one year ago, using pooled data from all regions, and stratified by gender/sexual orientation

